Titre indisponible

Le résumé fourni par la source

Objectives: To examine the pharmacokinetics of danaparoid sodium in patients undergoing continuous hemodiafiltration (CHDF). Methods: Six patients requiring CHDF with acute-disseminated intravascular coagulation (DIC) score above 4 points were enrolled in this study at Gifu Prefectural Tajimi Hospital between 2002 and 2005. They received a single i.v. injection of danaparoid sodium 1,250 units (1 ml). Anti-activated factor X activity (anti-Xa activity) in plasma was measured at 8 time points (before i.v. injection and 0.5, 2, 4 , 8 , 12 , 24, and 48 hours after i.v. injection). Results: Derived time-concentration data were analyzed pharmacokinetically using a two-compartment model, and elimination half life was estimated. Mean half-life of anti-Xa activity in plasma in the 6 patients was 27.1 hours, and about twice that in normal individuals (14.3 hours). However, mean anti-Xa activity in plasma returned to pre-injection level by 48 hours after i.v. injection. Conclusions: Our findings suggest that danaparoid sodium may be safely given to patients undergoing CHDF with consideration given to dosing interval. Further detailed studies of a large number of patients are needed to more clearly determine the pharmacokinetic characteristics of danaparoid sodium.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.